Unraveling the hurdles in the development of HER2-targeted agents for metastatic gastro-esophageal cancer patients

Gastric cancer (GC) is one of the most lethal cancers, representing the third leading cause of cancer-related deaths worldwide (1). In fact, more than two thirds of the cases of GC present metastatic widespread at diagnosis.